Invivyd Inc., a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, has appointed Timothy Lee as Invivyd’s Chief Commercial Officer and a member of the company’s executive leadership team.
 
Lee’s appointment follows the decision by the Board of Directors to eliminate the Chief Operating Officer role as part of its ongoing efforts to reallocate resources to support the launch of PEMGARDA, resulting in Jeremy Gowler’s departure. In the ongoing transitional period, Invivyd’s Chief Financial Officer, William Duke, Jr. will assume the role of Principal Executive Officer, and the Board of Directors will continue its ongoing search for a permanent Chief Executive Officer.

About Timothy Lee

Lee is a highly experienced commercial leader with an extraordinary track record of building commercial teams, leading successful product launches, and delivering strong results. Under his recent sales leadership at Amylyx, the commercial organization generated $390 million in net product revenue in 14 months and was on track to be in the top five orphan drug launches.
 
Lee also previously held key commercial leadership roles across a variety of life science companies including Biohaven Pharmaceuticals and Alexion Pharmaceuticals.
 
“Working together with the dedicated Invivyd team, I look forward to leveraging my network, experience and expertise to accelerate the company’s execution over the long term as we aim to provide durable protection to this population through serial innovation of best-in-class medicines,” said Lee.